Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Turing’s Shkreli Tussels With Express Scripts About ‘Ugly, Dirty Truth’ Of Drug Pricing

This article was originally published in The Pink Sheet Daily

Executive Summary

Martin Shkreli says he will not lower price of antiparasitic Daraprim, noting shareholders want firm to make as much money as possible; he thanks Express Scripts’ CMO for not excluding the drug.

Advertisement

Related Content

Drug Compounding Can't Be Justified By Price, FDA Says
Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register